Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;102(3):483-93; quiz 694.
doi: 10.1111/j.1572-0241.2007.01073.x.

Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus

Amitabh Srivastava  1 , Jason L Hornick, Xiaohong Li, Patricia L Blount, Carissa A Sanchez, David S Cowan, Kamran Ayub, Carlo C Maley, Brian J Reid, Robert D Odze
Affiliations

Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus

Amitabh Srivastava et al. Am J Gastroenterol. 2007 Mar.

Abstract

Objectives: Previous studies that evaluated extent of high-grade dysplasia (HGD) as a risk factor for esophageal adenocarcinoma (EA) in Barrett's esophagus (BE) were conflicting, and no prior study has evaluated extent of low-grade dysplasia (LGD) as a risk factor. The aim of this discovery study was to evaluate the hypothesis that extent of LGD and HGD are risk factors for progression to EA.

Methods: We evaluated baseline biopsies from 77 BE patients with dysplasia including 44 who progressed to EA and 33 who did not progress during follow-up. The total numbers of LGD and HGD crypts were determined separately by counting all crypts and the extent of LGD, HGD, and total dysplasia were correlated with EA outcome.

Results: Thirty-one and 46 patients had a maximum diagnosis of LGD and HGD, respectively. When the crypts were stratified by dysplasia grade, the mean number of LGD crypts per patient was borderline higher in progressors (93.9) compared with nonprogressors (41.2, P= 0.07), and the mean proportion of LGD crypts per patient was significantly higher in progressors (46.4%vs 26.0%, P= 0.037). Neither the mean number of HGD crypts per patient (P= 0.14) nor the mean proportion of HGD crypts per patient (P= 0.20) was significantly associated with EA outcome.

Conclusions: The extent of LGD is a significant risk factor for the development of EA in BE in this study. Although the presence of HGD is significantly associated with a greater relative risk for development of EA, the extent of HGD was not an independent risk factor for progression.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • Radiofrequency ablation for Barrett's dysplasia: past, present and the future?
    Haidry R, Lovat L, Sharma P. Haidry R, et al. Curr Gastroenterol Rep. 2015 Mar;17(3):13. doi: 10.1007/s11894-015-0433-5. Curr Gastroenterol Rep. 2015. PMID: 25740248 Review.
  • Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.
    Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA. Bennett C, et al. Gastroenterology. 2012 Aug;143(2):336-46. doi: 10.1053/j.gastro.2012.04.032. Epub 2012 Apr 24. Gastroenterology. 2012. PMID: 22537613 Free PMC article.
  • Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
    Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A, Cheng Y, Mori Y, Abraham JM, Yfantis HG, Wu TT, Fredericksen MB, Wang KK, Canto M, Romero Y, Feng Z, Meltzer SJ. Sato F, et al. PLoS One. 2008 Apr 2;3(4):e1890. doi: 10.1371/journal.pone.0001890. PLoS One. 2008. PMID: 18382671 Free PMC article.
  • Barrett esophagus: histology and pathology for the clinician.
    Odze RD. Odze RD. Nat Rev Gastroenterol Hepatol. 2009 Aug;6(8):478-90. doi: 10.1038/nrgastro.2009.103. Epub 2009 Jul 7. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19581906 Review.
  • American Gastroenterological Association technical review on the management of Barrett's esophagus.
    Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. Spechler SJ, et al. Gastroenterology. 2011 Mar;140(3):e18-52; quiz e13. doi: 10.1053/j.gastro.2011.01.031. Gastroenterology. 2011. PMID: 21376939 Free PMC article. Review. No abstract available.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources